Stock Report

Download full stock data and analysis for free Last Updated: 27-Aug-2026

Stock Rating

See the stock’s health at a glance, before it's too late.

Wealth Insight New Issue

This month’s issue could change how you invest, read now.

Recently Viewed

Clear All

Novartis India Peer Comparison

Stock Card factsheet watchlist-stock-modal share-fund-plan-icon

NSE: NOVARTIND | BSE: 500672

₹1,490.20

up-down-arrow ₹0.10 (0.01%)

As on 27-Aug-2026 15:31IST

Market cap

info icon

₹3,620 Cr

Revenue (TTM)

info icon

₹371 Cr

P/E Ratio

info icon

37

P/B Ratio

info icon

4.3

Div. Yield

info icon

0 %

Edit peer-selector-edit
Novartis India Wockhardt Rubicon Research Piramal Pharma Acutaas Chemicals
Market cap (₹ Cr)
 3,620 31,862 30,440 28,464 27,241
Revenue (₹ Cr)
 371 3,564 1,936 9,205 1,462
Net Profit (₹ Cr)
 97.77 414.00 288.22 -371.81 387.35
Net Margin (%)
 23.99 11.23 14.79 -3.93 26.01
RoE (%)
 12.28 8.38 29.77 -3.85 25.18
Price to Earnings
 37.03 77.90 105.62 -- 70.53
Price-To-Book
 4.26 6.33 22.68 3.56 15.76

Income Statement (₹ Cr)

Novartis India Wockhardt Rubicon Research Piramal Pharma Acutaas Chemicals
Operating Revenue arrow
370.59 3,564.00 1,935.80 9,205.28 1,461.80
Total Income arrow
407.49 3,686.00 1,948.58 9,449.59 1,489.25
Total Expenditure arrow
268.82 2,792.00 1,485.56 8,195.15 919.25
EBITDA arrow
101.77 772.00 450.24 1,010.13 542.56
Depreciation arrow
1.84 226.00 50.83 857.51 37.68
EBIT arrow
99.93 546.00 399.41 152.62 504.88
Interest arrow
1.22 217.00 40.84 342.73 3.77
Other Income arrow
36.90 122.00 12.78 244.31 27.45
Exceptional Items arrow
0.00 12.00 0.00 -216.88 0.00
Profit before Tax arrow
135.61 463.00 371.35 -162.68 528.56
Provision for Tax arrow
37.84 49.00 83.14 209.13 141.21
Profit after Tax arrow
97.77 414.00 288.22 -371.81 387.35

Liabilities (₹ Cr)

Novartis India Wockhardt Rubicon Research Piramal Pharma Acutaas Chemicals
Shareholder's Funds arrow
817.83 4,940.00 1,288.82 8,162.62 1,653.56
Minority Interest arrow
0.00 -5.00 0.00 0.00 -1.13
Non-Current Liabilities arrow
15.47 1,712.00 202.03 5,044.14 42.40
Current Liabilities arrow
144.97 1,622.00 835.87 4,758.28 230.82
Total Liabilities arrow
1,923.39 8,100.00 1,451.43 15,513.53 1,549.26

Assets (₹ Cr)

Novartis India Wockhardt Rubicon Research Piramal Pharma Acutaas Chemicals
Non-Current Assets arrow
14.29 5,343.00 519.60 10,211.52 1,026.85
Current Assets arrow
768.25 2,606.00 1,681.81 7,191.66 881.27
Total Assets arrow
1,923.39 8,100.00 1,451.43 15,513.53 1,549.26
Total Debt* arrow
0.00 1,859.00 393.17 4,720.27 8.18
Net Current Assets arrow
623.28 984.00 845.94 2,433.38 650.46
Contingent Liabilities arrow
378.34 770.26 12.25 99.76 15.38

Cashflow (₹ Cr)

Novartis India Wockhardt Rubicon Research Piramal Pharma Acutaas Chemicals
Cash From Operating Activities arrow
74.57 -22.00 159.18 892.30 118.34
Cash Flow from Investing Activities arrow
-3.31 -783.00 -64.81 -477.46 -223.94
Cash from Financing Activities arrow
-64.15 409.00 -39.81 -440.83 261.12
Net Cash Inflow / Outflow arrow
7.11 -396.00 54.56 -25.99 155.52

Ratios

Profitability Ratios

 Novartis India Wockhardt Rubicon Research Piramal Pharma Acutaas Chemicals
ROCE (%) arrow
17.15 4.07 26.97 6.61 20.14
ROE (%) arrow
12.28 8.38 29.77 -3.85 25.18
ROA (%) arrow
10.15 4.94 24.77 -2.21 21.93
EBIT Margin (%) arrow
26.97 15.32 20.63 1.66 34.54
Net Margin (%) arrow
23.99 11.23 14.79 -3.93 26.01
Cash Profit Margin (%) arrow
0.00 0.00 0.00 0.00 0.00

Growth Ratios

 Novartis India Wockhardt Rubicon Research Piramal Pharma Acutaas Chemicals
Revenue Growth (%) arrow
5.42 18.37 46.65 0.78 40.90
EBIT Growth (%) arrow
8.01 252.26 62.13 -70.53 124.50
Net Profit Growth (%) arrow
-4.87 377.85 89.49 -1,383.43 104.15
EPS Growth (%) arrow
-4.87 1,001.33 78.60 -484.84 42.32
Book Value Growth (%) arrow
5.39 29.77 42.49 2.28 94.96

Valuation Ratios

 Novartis India Wockhardt Rubicon Research Piramal Pharma Acutaas Chemicals
Price / Earnings arrow
37.63 76.67 102.64 -89.97 69.15
Price / Book Value arrow
4.33 6.07 22.38 3.52 15.45
Dividend Yield (%) arrow
0.00 0.00 0.08 0.00 0.08
EV/EBITDA arrow
29.78 41.47 66.53 31.97 48.78
Market Cap (₹ Cr) arrow
1,937.50 23,064.69 0.00 29,731.27 19,988.69

Solvency Ratios

 Novartis India Wockhardt Rubicon Research Piramal Pharma Acutaas Chemicals
Debt to Equity arrow
0.00 0.31 0.11 0.53 0.01
Short term debt to equity ratio arrow
-- 0.11 0.54 0.12 0.02
Current Ratio arrow
5.30 1.61 2.01 1.51 3.82
Quick Ratio arrow
4.93 1.06 1.14 0.87 2.82
Interest Coverage arrow
112.16 3.13 10.09 0.53 141.16

Operating Efficiency Ratios

 Novartis India Wockhardt Rubicon Research Piramal Pharma Acutaas Chemicals
Debtors to sales (%) arrow
10.00 16.50 26.28 23.44 24.80
Asset Turnover arrow
0.38 0.43 1.66 0.55 0.83
Receivable days arrow
38.18 60.36 47.59 77.05 90.06
Inventory Days arrow
40.22 64.42 62.58 77.13 61.02
Payable days arrow
101.73 218.94 228.78 173.49 96.06
Cash Conversion Cycle arrow
-23.33 -94.15 -118.62 -19.30 55.02
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
loading...